American Diabetes Association
Browse
cd22-0096_Supplementary_Material,_FINAL.pdf (171.27 kB)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 units/mL or Detemir 100)

Download (171.27 kB)
figure
posted on 2023-03-28, 14:37 authored by Steven Edelman, Jennifer Goldman, Daniel C. Malone, Ronald Preblick, Kovida Munaga, Xuan LiXuan Li, Jasvinder Gill, Sumana Gangi

  

People with type 2 diabetes receiving a second-generation basal insulin (BI) analog may be switched to a first-generation formulation for financial reasons or changes in health insurance. However, because second-generation BI analogs have more even pharmacokinetic profiles, longer durations of action (>24 vs. ≤24 hours), and more stable action profiles than first-generation BI analogs, such a change may result in suboptimal treatment persistence and/or adherence. This study compared treatment persistence, treatment adherence, rates of hypoglycemia, and health care resource utilization outcomes in people with type 2 diabetes who either continued treatment with the second-generation BI Gla-300 or switched to a first-generation BI.  The study showed that continuing with  Gla-300 was associated with a lower risk of discontinuing therapy, fewer emergency department visits, and lower hypoglycemia event rates than switching to a first-generation BI.

Funding

Sanofi US

History

Usage metrics

    Clinical Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC